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Equine Dental Pulp Connective 
Tissue Particles reduced lameness 
in Horses in a Controlled Clinical Trial
Alicia L. Bertone*, Nathalie A. Reisbig, Allison H. Kilborne, Mari Kaido,  
Navid Salmanzadeh, Rebecca Lovasz, Joy L. Sizemore, Logan Scheuermann,  
Rosalind J. Kopp, Lisa J. Zekas and Matthew T. Brokken
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA
Objective: To assess if injection of allogeneic dental pulp tissue particles would improve 
lameness in horses with naturally occurring osteoarthritis (OA) or soft tissue (ST) injury.
Design: Prospective, randomized, blinded, and controlled clinical trial and client survey 
assessment.
animals: Forty lame client-owned horses.
Procedures: Sterile dental pulp, recovered from otherwise healthy foals that perish during 
dystocia, was processed under good manufacturing processing to produce mechani-
cally manipulated, unexpanded pulp tissue particles containing viable cells surrounded 
in extracellular matrix. Forty lame client-owned horses with confirmed OA (n = 20), or ST 
injury (desmitis or tendonitis) received a 2 mL intra-articular (n = 20 OA) or intra-lesional 
(n = 20) injection of control transport vehicle (n = 20) or 10 × 106 dental pulp tissue 
particles (n = 20). Acclimatized horses had baseline measurements performed and were 
then injected on day 0. Horses were treadmill exercised for 2 weeks, evaluated by clinical 
parameters, lameness score, edema (score and circumference), pain on flexion (OA) or 
pressure (ST), and clients’ scores for pain and discomfort before and through 45 days 
after pulp injection. Twenty horses were available for >2.5-year follow-up.
results: Pulp-treated horses showed decrease in lameness compared to baseline 
(P < 0.009) or placebo controls (P < 0.013) for at least 2 weeks. Client assessments 
of comfort were improved between before and 45 days after pulp injection (P < 0.001). 
Clinical improvement with ST injury was significantly greater than OA (P < 0.001). At 
>2.5-year follow-up, at least 10 horses were in work.
Conclusion and clinical relevance: Dental pulp tissue particles can be considered as 
a treatment option for equine lameness due to OA, desmitis, or tendonitis.
Keywords: dental pulp, osteoarthritis, lameness, desmitis, tendonitis
Abbreviations: AAEP, American Association of Equine Practitioners; CBC, complete blood count; DDF, deep digital flexor 
tendon; GMP, good manufacturing processing; IL-1ra, interleukin-1 receptor antagonist; IL-1β, interleukin-1β; IL-6, interleu-
kin 6; IL-10, interleukin 10; OA, osteoarthritis; PRP, platelet-rich plasma; SDF, superficial digital flexor tendon; ST, soft tissue; 
WBC, white blood cell.
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inTrODUCTiOn
Tissue allografts (fresh or frozen) and decellularized extracel-
lular matrix allografts have been used to support osteochondral 
defects, soft tissue (ST) healing, as well as vascular and ligament 
replacement for decades (1–3). Allogeneic multipotent mesen-
chymal stromal/stem cells (MSCs), either isolated or in matrix, 
potentially offer advantages over autologous tissues for use in 
regenerative therapies due to lack of patient morbidity at a donor 
site, well-characterized cells or tissues, accredited manufacturing 
practices and labeling standards, and practical “off the shelf ” 
access (4–9). A few recent publications in horses have shown 
measurable differences in clinical response of joints to allogeneic 
compared to autologous cells (4, 10, 11), however, responses 
were either not statistically different from controls (11) or were 
minimal (10) or considered manageable (4). Several human 
clinical trials have proceeded with allogeneic biologics such as 
particulated juvenile cartilage allografts1 and engineered cartilage 
allografts2 for the treatment of cartilage defects and osteoarthritis 
(OA). For human cells, successful efficacy for cartilage repair has 
been demonstrated with allogeneic MSCs and chondrocytes (6, 8, 
9, 12–15). Success of these cell-based biologic products has been 
ascribed to viable progenitor cells that could migrate, engraft, 
differentiate, and facilitate tissue regeneration (16), but more 
recently it has been recognized that MSC have anti-inflammatory 
(17, 18), immunomodulatory (5, 19, 20), and pain-relieving 
effects (21–23). Several available commercial devices can produce 
equine patient-side viable cell concentrates of bone marrow,3,4,5 or 
adipose tissue,6,7 and are designed for autologous use. However, 
without culture of the bone marrow or adipose tissue, progenitor 
and stem cell yields are low (<0.002%) (24, 25). Several studies 
in horses have specifically supported the use of these cultured 
processed MSC as therapy for joint and cartilage disease (26–30) 
as well as ST injury such as tendonitis and desmitis (7, 31, 32). 
Due to reported success of MSC in these painful lameness condi-
tions in horses, we focused our lameness population to cartilage 
degeneration and tendonitis/desmitis as target diseases with the 
primary outcome of lameness relief.
In humans, dental pulp connective tissue obtained from the 
base of extracted wisdom teeth has been cryopreserved (33) and 
progenitor neural, bone, and ligament cells isolated and studied 
1 Post-market study of articular cartilage defects of the knee treated with DeNovo 
NT, Natural Tissue Graft NCT00791245. Zimmer Orthobiologics May 3, 2016. 
https://clinicaltrials.gov/ct2/show/NCT00791245?term=carilgae+repair&r
ank=11.
2 Randomized controlled trial to evaluate the efficacy of a neocartilage implant 
in the management of ICRS grades 3–4 articular cartilage lesions of the knee 
(Neocartilage Implant/DeNovo®ET Engineered Tissue Graft) May 3, 2016. https://
clinicaltrials.gov/ct2/show/NCT01400607?term=cartilage+repair&rank=12.
3 MarrowStem® and BioCUE™ BBMA (blood and bone marrow aspirate). www.
biomet.com.
4 EStem®, Pall Corporation. www.pall.com.
5 Harvest® Bone Marrow Aspirate Concentrate (BMAC®) System. www.harvest-
tech.com.
6 InGeneron Incorporated, ARC™ (adipose-derived regenerative cells) System. 
www.ingeneron.com.
7 VetCell Therapeutics, ReGen OA (adipose-derived regenerative cells). http://
vetcelltherapeutics.com.
for regenerative potential. Dental pulp from un-erupted tooth 
buds in humans can be harvested with low morbidity to the 
donor. Cells can be cryopreserved (33), and subsequently thawed 
to produce a viable cell for allogeneic or autologous injection. 
To our knowledge, the study of a dental pulp tissue injectable 
particulate in horses has not been reported. Dental pulp for the 
generation of this tissue particulate is obtained from otherwise 
healthy foals that died during the birthing process (dystocia) 
using sterile extra-oral harvest techniques by a dedicated sur-
geon using good tissue practice methods routine for collection of 
human tissue for allogeneic transplantation. Minimally manipu-
lated tissue processing results in a characterized product, that is 
available as an “off-the-shelf ” cell and matrix product for easy 
use in practice and avoids some of the limitations with currently 
reported tissue sources. These limitations for current sources, 
that are either not a limitation or much reduced limitation for 
dental pulp, include, for differentiated tissue such as skin and 
blood, low stem cell yields that often require extraction (34, 35) 
or mobilization (36), respectively. Umbilical cord and amnion 
can be contaminated at birth increasing the potential risk of 
infection in the stem cell harvests. Bone marrow progenitor cell 
yields are variable due to blood contamination (25), and the 
procedure can be a risk or painful to the donor (25). Oocytes 
and other embryonic or fetal sources raise ethical concerns 
for human tissues and carry the concern of teratogenesis and 
carcinogenesis (32, 37, 38). Adipose-derived cells require an 
invasive procedure for harvest and are limited by non-homol-
ogous use clauses by regulatory agencies even for autologous 
use.8 Therefore, dental pulp offers a biologic therapy option with 
benefits of minimally processed tissue, successful cryopreserva-
tion, high density of pluripotent cells, avoidance of on the farm 
processing and product variability, and lack of donor morbidity. 
Additionally, this promising tissue source of allogeneic stem 
or progenitor cells has been studied in human tissue and cells 
(33, 39–48). The high concentration of human progenitor cells 
in un-erupted dental pulp resulted in robust harvest yields of 
undifferentiated cells that have been characterized (39). Dental 
pulp has recently served as a source of human pluripotent cells 
destined for differentiation into bone (40–42), blood vessels (43, 
44), ligament (45), and, uniquely, neural tissue (46–48) result-
ing in a menu of homologous applications. Human dental pulp 
has been expanded in culture or immediately cryopreserved 
and banked (33). To our knowledge, there are no publications 
on dental pulp as a biologic therapy in horses. Our study will 
report, in horses, on an injectable mechanically manipulated 
dental pulp connective tissue particulate9 composed of dental 
pulp cells and extracellular matrix containing growth factors 
from within the cells and matrix (Figure 1; Tables 1 and 2; see 
Preliminary Data). These tissue constituents could bring anti-
inflammatory and regenerative capabilities to the joint, tendon, 
or ligament environment (47–50). Dental pulp tissue particles 
8 Cell-based products for animal use. Guidance for Industry #218. Center for 
Veterinary Medicine (HFV-114), Food and Drug Administration. http://www.fda.
gov/AnimalVeterinary/default.htm or http://www.regulations.gov.
9 Pulpcyte® StemLutions (currently VetGraft) Columbus, OH, USA. www.
VetGraft.com.
TablE 1 | Cell viability and receptor expression phenotype immediately 
post-thaw from equine dental pulp tissue particles as analyzed by flow 
cytometry (n = 25 samples).
Viability CD45 CD34 CD44 CD90 CD105
Mean (%) 99.05 63.93 79.26 73.94 81.53 63.11
SD 2.50 31.53 22.37 14.62 13.16 17.05
FigUrE 1 | (a) Fluorescent confocal microscopy images of dental pulp cell 
tissue particles showing sheets of cells held together by extracellular matrix. 
Rounded, raised areas are nuclei and cell borders are indescript due to the 
attached matrix. The cytoplasm staining green (live) is positive for cell viability 
(LIVE/DEAD®1). (b) Counter-staining with ethidium homodimer red (dead) 
shows that some cells are non-viable as the nuclei stain red.
1 LIVE/DEAD® Viability/Cytotoxicity Kit, Thermo Fisher Scientific, Waltham, 
MA, USA.
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offer a potential alternative or addition to non-steroidal anti-
inflammatory drugs or steroids for pain, and with regenerative 
potential unlike either of those products.
In our study, we used this novel viable dental pulp tissue 
particulate injectable solution (see text footnote 9) that is a mini-
mally manipulated, mechanically processed, unexpanded viable 
connective tissue targeted for allogeneic use in equine muscu-
loskeletal painful conditions that have reportedly responded 
to cell-based therapies in horses, specifically joint, tendon, and 
ligament injury (7, 22, 26–31). We predicted that dental pulp, 
minimally and mechanically processed, used as an injectable 
treatment for painful ST injury (tendonitis or desmitis) or OA, 
would affect those events associated with tissue injury (pain 
and inflammation) and result in less lameness. Growth factors 
within or stimulated by the dental pulp tissue treatment may also 
have the potential to prevent tissue degeneration and be disease-
modifying (48–50).
We aimed to determine if injection of equine allogeneic 
dental pulp tissue particles into naturally occurring equine cases 
of inflamed injured tendon or ligament or OA joints would alter 
lameness and other parameters of pain, produce inflammation 
at the injection site, or show disease-modifying criteria as meas-
ured by joint biomarkers. We targeted the painful conditions of 
OA, tendonitis, or desmitis (ST injury) and used a prospective 
blinded randomized controlled clinical trial under tight environ-
ment control and with quantitative outcomes as our design. Our 
hypothesis was that injection of test article (see text footnote 9) 
would have significant improvements in outcomes related to 
lameness (scores and force plate parameters), pain (joint flex-
ion, lesion pressure), or inflammation (circumference, scores) 
as compared to an injection of a similar volume of the carrier 
vehicle without dental pulp particles.10 Based on prior publica-
tions it was anticipated that, if there was an influence, this could 
be proven within 2 weeks (22). Additionally and simultaneously, 
we performed a client assessment of comfort using a validated 
survey in a prospective manner such that baseline scores allowed 
each horse to serve as its own control. The impact of this work 
would be to, first, potentially prove that dental pulp tissue par-
ticles can reduce lameness and pain in horses affected with one 
of our most common diseases causing lameness and, second, 
that client assessment of improvement in comfort and satisfac-
tion will support this finding. Additionally, long-term surveys 
could document that previously injected horses that could not 
perform at the time of enrollment could return to work without 
associated adverse life-threatening events or worsening of their 
condition.
PrEliMinarY DaTa
Equine Dental Pulp Tissue Particle Cellular 
Characterization
The dental pulp connective tissue’s minimal processing results 
in particles of cells and ECM less than 100 μm in size with a 
hydrodynamic average diameter of 20 μm. Pulp tissue particles 
are mostly ECM and cell(s) bound together but also occasional 
ECM or cell(s) alone. Many of the larger particles (>50  μm) 
contain multiple cells. There are 10 × 106 ECM/cell(s) particles in 
each 2 cc injection. Cellular characterization was performed on 
cryopreserved vials of dental pulp connective tissue particulate 
suspension from 25 different tissue donations, thawed from the 
−80°C quarantine freezer and placed in a bio-laminar flow hood. 
Seven culture test tubes were labeled as follows: (1) unlabeled, 
(2) CD34-FITC (11-0341-8211), (3) CD45-PE [12-0450-82 
(see text footnote 12)], (4) CD44-FITC [12-0441-82 (see text 
footnote 12)], (5) CD90-PE [12-0909-42 (see text footnote 12)], 
(6) CD105-PE [12-1051-82 (see text footnote 12)], and (7) pro-
pidium iodide [00-6990-50 (see text footnote 12)]. The thawed 
tissue suspension was washed and re-suspended in 2.10 mL of 
transport solution. Tissue suspension (300  μL) was pipetted 
into each of the labeled culture tubes to which 20  μL of the 
appropriate antibody was added. No antibodies were added to 
the unlabeled cell population, but the same steps were completed 
as for samples with antibodies. Cells were placed at 8°C in the 
dark for 30 min, and tubes were vortexed at the 15 min mark. 
After 30 min, sterile transport solution was added to each tube 
and centrifuged at 1,800 RPM for 7 min at room temperature. 
After decanting, the cells were re-suspended in 500 μL of sterile 
transport media. Aluminum foil was placed around the tubes to 
10 Sterile Isotonic Saline Solution (manufactured under ISO 9001 and 13485), 
Preservation Solutions, Elkhorn, WI, USA.
11 eBiosciences. www.ebioscience.com.
TablE 2 | Detection and annotation of selected prevalent proteins, found in three samples, in extracellular matrix of equine dental pulp particles by 
liquid chromatography and mass spectroscopy.
Protein name Protein accession numbers Function summary
Actin ACT17_DICDI Various cellular functions such as cytoskeleton structure, cell mobility, chromosome movement, and muscle 
contraction
Annexin A1 ANXA1_HORSE Role in the innate immune response as effector of glucocorticoid-mediated responses and regulator of 
the inflammatory process. Has anti-inflammatory activity. Promotes resolution of inflammation and wound 
healing
Biglycan PGS1_HORSE May be involved in collagen fiber assembly
Collagen 1 CO6A1_HUMAN Collagen precursor
Collagen 2 CO6A1_MOUSE Collagen precursor
Collagen 3 CO6A3_HUMAN Collagen precursor
EMILIN-1 EMIL1_HUMAN May be responsible for anchoring smooth muscle cells to elastic fibers, and may be involved not only in 
the formation of the elastic fiber, but also in the processes that regulate vessel assembly. Has cell adhesive 
capacity
Fibronectin FINC_HORSE Bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins 
are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. 
Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly 
process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by 
osteoblasts
Heat shock protein 
beta
HSPB1_BOVIN Involved in stress resistance and actin organization
Hyaluronan and 
proteoglycan link 
protein 1
HPLN1_HORSE Stabilizes the aggregates of proteoglycan monomers with hyaluronic acid in the extracellular cartilage matrix
Myosin MYH9_CANFA Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as 
secretion and capping. During cell spreading, plays an important role in cytoskeleton reorganization, focal 
contacts formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; 
this function is mechanically antagonized by MYH10
Pentraxin-related 
protein PTX3
PTX3_MOUSE Plays a role in the regulation of innate resistance to pathogens, inflammatory reactions, possibly clearance of 
self-components
Putative actin-25 ACT25_DICDI Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously 
expressed in all eukaryotic cells. Multiple isoforms are involved in various cellular functions such as 
cytoskeleton structure, cell mobility, chromosome movement, and muscle contraction
Serpin H1 SERPH_BOVIN Binds specifically to collagen. Could be involved as a chaperone in the biosynthetic pathway of collagen
Serum albumin ALBU_HORSE
60 kDa heat 
shock protein, 
mitochondrial
CH60_PONAB Implicated in mitochondrial protein import and macromolecular assembly. May facilitate the correct folding of 
imported proteins. May also prevent misfolding and promote the refolding and proper assembly of unfolded 
polypeptides generated under stress conditions in the mitochondrial matrix
Transforming 
growth factor-
beta-induced 
protein
BGH3_HUMAN Plays a role in cell adhesion. May play a role in cell–collagen interactions. Binds to type I, II, and IV collagens
Tubulin TBA_ENTDO, TBB1_GADMO Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on 
the beta chain and one at a non-exchangeable site on the alpha chain
Versican core 
protein
CSPG2_HUMAN, CSPG2_MOUSE May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in 
the regulation of cell motility, growth, and differentiation. Binds hyaluronic acid
Vimentin VIME_BOVIN, VIM4_XENLA, 
VIMB_CARAU
Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal 
cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or 
terminally
Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2
One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is 
enhanced during cell division, at which time vimentin filaments are significantly reorganized
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FigUrE 2 | graph of total nucleated cell counts from synovial fluid of 
sound horses’ normal joints injected with transport control vehicle 
(blue) or dental pulp tissue particles (red) or lame horses’ 
osteoarthritic joints injected with dental pulp tissue particles (green). 
Joints with osteoarthritis had a greater nucleated cell count than normal joints 
at day 1 after injection.
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protect them from light. The foiled tubes were transported in a 
cooler with an ice pack and brought to the flow cytometry lab at 
the university to have the cells analyzed.12 Cells were >99% viable 
post-thaw (Table 1). Confocal live/dead fluorescent microscopy 
assay (see text footnote 10) of the dental pulp tissue particles also 
showed a majority of live cells that were surrounded by a varying 
amount of extracellular matrix in some cases maintaining the 
cells as layered sheets (Figure 1). In conclusion, equine dental 
pulp cells highly expressed progenitor and stem cells markers, 
from both hematopoietic (CD45+ and CD34+) progenitor lines, 
as well as mesenchymal (CD44, CD90, and CD105) progeni-
tor lines, indicating a primordial cell capable of multi-lineage 
differentiation.
Equine Dental Tissue Pulp Particle 
Extracellular Matrix Protein 
Characterization
The extracellular matrix was analyzed for protein composi-
tion using liquid chromatography and mass spectroscopy13 
and the annotated proteins with the greatest prevalence were 
summarized from positive hits for 253 proteins in the extracel-
lular matrix. The most prevalent proteins were annotated and 
categorized by function according to the National Center for 
Biotechnology Information14 and included many proteins with 
anti-inflammatory activity (Annexin A1), structural elastic, and 
adhesion activities in MSC (vimentin, versican core protein, 
tubulin, myosin, fibronectin, EMILIN-1, collagen 3), proteins of 
stress resistance, fiber assembly, and compressibility (biglycan, 
heat shock protein, hyaluronan, proteoglycan link protein, serpin 
H1), growth factors (transforming growth factor-beta-induced 
protein), and innate pathogen resistance (pentraxin-related 
protein PTX3) (Table 2). In conclusion, many of these proteins 
could serve a function as anti-inflammatory and/or regenerative 
in inflamed and healing tissue.
Pilot Equine Studies in normal Horses
Three adult, university owned, research horses with no muscu-
loskeletal abnormalities in the bilateral forelimb fetlock joints, at 
day 0, had one randomly chosen forelimb fetlock joint injected 
with 1 × 106, 5 × 106, or 10 × 106 equine dental pulp tissue particles 
as 1 mL volume in transport vehicle, and the contralateral fetlock 
joint was injected with the equivalent volume (1 mL) of transport 
vehicle alone. Joint fluid from both joints were obtained at days 
0, 1, 2, 7, and 14, and analyzed for total protein concentrations, 
white blood cell (WBC) count, and neutrophils (%). Pain and 
swelling of each joint was assessed at days 0, 1, 2, 3, 7, and 14, by 
measuring joint circumference (centimeters), joint swelling score 
(0–4), pain-free range of joint motion (degrees), and pain on 
flexion score (0–4) as described in more detail in the main study. 
12 Becton Dickinson LSR-II flow cytometer.
13 Thermo LTQ_XL Orbitrap, Bruker Maxis. https://cancer.osu.edu/research-and- 
education/shared-resources/proteomics/services.
14 www.ncbi.nlm.nih.gov.
Lameness was assessed at days 0, 3, 7, and 14, by using a lameness 
grading scale from 0 to 5, before and after flexion of the injected 
joints. Venous blood was drawn at days 0 and 14 and analyzed by 
complete blood count (CBC) and chemistry panel, and the body 
weight was measured at days 0, 7, and 14. This dose escalation 
study demonstrated similar synovial fluid inflammation of the 
vehicle alone and the 1 × 106 or 5 × 106/mL dose (Figure 2). Based 
on these findings, the dose of 5 × 106/mL was selected for use in 
subsequent studies to maximize the dose along with minimizing 
the inflammation.
Pilot Preclinical Oa Study
Three adult, university owned, research horses, diagnosed with 
OA in a radiocarpal, midcarpal joint, or hindlimb fetlock joint, 
were used in this pilot study. Inclusion criteria included a score 
>2 for lameness and radiograph within 30 days demonstrat-
ing signs of OA including osteophyte formation, joint space 
irregularity or narrowing. At day 0, the affected joint was 
injected with 5 × 106 allogeneic dental pulp tissue particles in 
1  mL of transport vehicle. Other parameters measured were 
similar to the dose escalation study. The results showed an 
increase in synovial fluid WBC count on days 1 and 2 after 
injection, greater than in normal horses (Figure 2). No lame-
ness was detected in limbs injected with vehicle or 5 × 106 dose 
in normal sound horses, and lameness decreased (P < 0.001) 
in OA horses between days 0 and 14 (Figure 3). Joint swelling 
scores, pain-free range of joint motion, and pain on flexion 
scores were not significantly different among groups or any 
time point. Swelling was localized to the joint and modest 
in amount. There was no significant difference in any blood 
parameters measured among groups or between time points 
(days 0 and 14).
FigUrE 3 | graph of lameness scores of sound horses’ normal joints 
injected with transport control vehicle (blue) or dental pulp tissue 
particles (red) or lame horses’ osteoarthritic joints injected with 
dental pulp tissue particles (green). Lameness in horses with 
osteoarthritis significantly improved (P < 0.05) from baseline to day 14.
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MaTErialS anD METHODS
Prospective, randomized, blinded, and 
Placebo-Controlled Clinical Trial Design
Forty lame horses [American Association of Equine Practitioners 
(AAEP) lameness grades 2–5 (22); age range 2–18 years] with OA 
(n = 20), or with ST injury, either desmitis or tendonitis (n = 20), 
were assigned, by use of an online random number generator,15 
into either a treatment group (n = 20) or control group (n = 20) 
based on serial enrollment within OA or ST diseases. At day 0, 
the horses in treatment and control groups received an injection 
of dental pulp tissue particles (see text footnote 9) or control ster-
ile buffered isotonic saline transport solution (see text footnote 
11), respectively. All horses were evaluated by physical examina-
tion’s (day 0, day 7, day 14), blood analysis (screening, day 2, day 
14) and joint synovial fluid analysis (OA; day 0, day 14), use of 
subjective lameness grade scores (AAEP 0–5; baseline, day 7, day 
14), as well as measuring or grading inflammation parameters 
{edema, limb circumference [baseline, days 1 (edema only), 2, 
4, 7, 10, 14]}, pain score on palpation (ST), goniometric range 
of motion (OA), lameness pain score on pressure (ST; baseline, 
days 2, 4, 7, 10, 14), and pain score on lameness flexion (OA; 
day 0, day 7, day 14). Ultrasound (baseline, day 7, day 14) and 
radiography (baseline, day 14) were also performed. Horses were 
confined to a 12′ × 12′ boxstall and exercised twice weekly on 
a treadmill for the duration of the study. Owners were blinded 
as to the assignment for the duration of this study. After study 
termination at day 14, owners of horses in the control group 
were offered the option for their horses to receive an injection 
of dental pulp tissue particles following the same protocol as the 
treatment group.
15 Stat Trek. Available at: http://stattrek.com/statistics/random-number-generator.
aspx. Accessed Jan 6, 2016.
Prospective Client assessment Study 
Design
All clients with horses enrolled in the prospective, randomized, 
blinded, and placebo-controlled clinical trial were simultaneously 
enrolled in a client assessment study of their horses’ status using 
a survey that corresponded to lameness and pain in our prior 
work (22).16 Clients enrolled at the start of the study prospectively 
agreed to complete all forms at the times on the protocol, which 
was before assignment of their horse into the clinical trial and 
at days 21 and 45 after injection. To complete the survey, the 
horse was to be observed in several different activities over a day 
or so until the client was comfortable that the scores reflected 
the condition of the horse. These assessments were direct visual 
observation by the client and data recorded on our survey ques-
tionnaire form, signed and dated by the client. Clients performed 
visual assessments requested by the questionnaire on their horse 
in the horse’s home environment before transportation to the 
study site for enrollment. Owner’s committed in the signed 
consent form that their horse’s environment would remain the 
same until after the final questionnaire. Their first post-injection 
assessment would occur shortly after the horse returned home 
and another in 3–4 weeks after the horse returned home. Clients 
were instructed to return the horse to the level of activity they were 
on prior to enrollment at their baseline assessment, only varied 
if recommended by the author (Alicia L. Bertone). Both before 
the enrollment and at enrollment, each client had a discussion 
session with the author (Alicia L. Bertone) to go over the forms 
and answer any questions the client may have had in interpreting 
the questions in the survey. Seven categories were graded by the 
client on a Likert scale ranging from 0 to 10: degree of lameness 
(0 =  sound; 10 =  won’t bear weight), comfort at rest in stall 
(0 = comfort; 10 = discomfort), comfort at turnout (0 = com-
fort; 10 =  discomfort), general attitude (0 =  bright, alert, and 
interactive; 10 = dull, signs of depression, and non-interactive), 
appetite (0 = eats all food and looks for more; 10 = will not eat), 
body condition (0 =  excellent; 10 =  poor), and hair condition 
(0 = excellent; 10 = poor). All client assessments were blinded 
at baseline assessment and unblinded at follow-up because all 
horses received dental pulp tissue particle injection at either day 
0 or after day 14 resulting in a lower level of evidence than the 
prospective randomized blinded placebo-controlled clinical trial. 
This client assessment study, however, did meet several require-
ments that supported a level of evidence for these data. Clients 
were instructed in the use of the survey and signed and dated all 
forms as part of the good clinical practice standards used for this 
trial. All horses were on the same environmental protocol and 
outcome assessments creating a tightly controlled group of lame 
horses that had met strict inclusion criteria for their pain and 
lameness along with a confirmed diagnosis with the result of a 
tight data set for the client’s assessments. Horses were randomly 
assigned to the study conditions and conditions at home were 
maintained for both baseline and post-injection assessments. All 
16 Prospective, randomized, blinded, and controlled clinical trial (Bertone PI) to 
study reduction in pain and lameness by opioids for distal limb pain in horses, 
data unpublished, 2014.
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clients (100%) were enrolled to complete this validated question-
naire as part of the study at defined times, and all enrollments 
were completed within a 6-month time frame. For this phase, 
each horse served as its own control. Additionally, the clients 
were queried by the author (Alicia L. Bertone) for adverse events 
including worsening of lameness and any events were recorded 
on the adverse event form, signed, and dated. These same clients 
were contacted by phone or email 2.5–3 years after injection and 
answered the same questionnaire.
inclusion Criteria
At admission horses had to have a diagnosis of lameness due to 
clinical evidence of OA, desmitis, or tendonitis. Diagnosis of OA, 
desmitis, or tendonitis was determined within 30 days prior to or 
at arrival for enrollment by use of lameness, radiographic exami-
nation, ultrasound examination and, when indicated, diagnostic 
anesthesia to confirm the location of the lameness. Clinical criteria 
for OA were defined as lameness, joint swelling, pain or reduc-
tion in joint flexion in the presence of radiographic osteophytes, 
subchondral bone sclerosis, or narrowing of the joint space. 
Clinical criteria for desmitis were defined to include lameness 
with ultrasonographic changes indicating areas of enlargement, 
a hypoechoic pattern (indicative of edema), or disruption of 
fiber pattern in the suspensory ligament. Tendonitis maintained 
the same definition as desmitis but signs in conjunction with 
lameness could be the aforementioned ultrasound changes for 
desmitis or a visual lateral profile of superficial digital flexor ten-
don (SDF) or deep digital flexor tendon (DDF) swelling or pain 
on pressure of the SDF or DDF. For study purposes, all lameness 
scores on initial evaluation had to fall between 2 and 5 on the 
AAEP scale and be at least 4 weeks in duration. Exclusion criteria 
included presence of an infection, unstable fracture, or to have 
received tendon, ligament or joint injection (within 2 months), 
or surgery (within 6 months). All procedures were approved by 
the Institutional Animal Care and Use Committee. Informed 
consent was obtained from owners of horses before enrollment 
in the study. All horses had jugular venous blood submitted for 
CBC before and at the termination of the study.
Equine Dental Pulp Tissue Processing
These dental particle allografts were mechanically dissociated 
with disposable sterile tissue grinders, counted and re-suspended 
at a concentration of 5 ×  106 cell particles/mL, cryopreserved, 
and stored in liquid nitrogen for long-term storage. For the dental 
pulp tissue particles used in this study, tissue was thawed, washed 
and centrifuged, and re-suspended at a concentration of 5 × 106/
mL in a sterile isotonic buffered saline solution (see text footnote 
11), ready to inject. Prior to cryopreservation and prior to injec-
tion, dental pulp tissue particles were tested for transmissible 
diseases including microbial, fungal, and viral as per American 
Association of Tissue Bank guidelines.17 Post-thaw viability was 
17 Standards for Tissue Banking, the American Association of Tissue Banks 
(February 29, 2012—13th edition) McLean, VA, USA. www.atb.org.
confirmed with flow cytometry (propidium iodide). Particles 
diluted to aforementioned dose concentrations, were shipped 
overnight to the clinician for immediate injection or storage at 
8°C for up to 10 days.
Treatment
Injections of either dental pulp tissue particles suspended in 
sterile buffered isotonic saline solution (5 × 106 particles/mL) or 
the sterile buffered isotonic saline solution without pulp particles 
(placebo control) were delivered on day 0 as 2.5 mL samples to 
the study site and placed in a dedicated, locked refrigerator, in 
a coded vial for blinding, until used. After day −1 and before 
injection, all baseline parameters were recorded. At day 0 in OA 
horses, joint fluid aspiration followed by intra-articular injection 
of dental pulp tissue particles (treated group; 2 mL of transport 
solution containing 10 × 106 pulp tissue particles) or transport 
solution (control group; 2 mL) was performed by one investigator 
(Alicia L. Bertone), who was kept unaware of treatment assign-
ments. Aspiration of, and injection into, the joints was performed 
by passing a needle percutaneously into the joint after clipping 
and aseptic preparation of the injection site. Joint fluid aspiration 
confirmed needle placement in the joint and up to 5.0 mL was 
aspirated prior to the injection. The fluid withdrawn was submit-
ted for standard synovial fluid analysis and cytology.18 Remaining 
synovial fluid was frozen at −20°C for ELISA analysis of biomark-
ers interleukin-1 receptor antagonist (IL-1ra), interleukin-1β (IL-
1β), interleukin 6 (IL-6), and interleukin 10 (IL-10).19 Bandages 
were not applied after the joint aspiration and injection. At day 
14, joint fluid aspiration was performed again in all OA horses. 
For control OA horses, aspiration was followed by intra-articular 
injection of dental pulp tissue particles after day 14, if elected by 
the client, following the same protocol as for the treatment group.
At day 0 in ST horses, the epicenter of the ST lesion was 
located with ultrasound, marked with a skin staple, and injected 
percutaneously, after an aseptic preparation as described above 
for joint injection, with 2  mL of transport solution containing 
10 × 106 pulp tissue particles (treated group) or 2 mL transport 
solution (placebo-control group). All injections were performed 
by one investigator (Alicia L. Bertone).
Exercise
Horses were exercised twice per week on a high-speed equine 
treadmill20 for 10 days of acclimation and 2 weeks of the study 
with the following regimen: walking (7.2 km/h) for 10 min, fol-
lowed by trotting (14.4 km/h) for 10 min, and walking (7.2 km/h) 
for 10  min. If horses were or became lame at the walk on the 
treadmill, they were not trotted and were exercised at the walk 
only or hand-walked. Throughout the experiment, the horses 
were housed individually in stalls in a temperature-controlled 
environment, fed a commercial grain mixture twice daily, and 
provided access to hay and water ad libitum. No medications or 
18 Clinical Pathology Laboratory, The Ohio State University, Columbus, OH, USA.
19 R&D Systems Inc., Minneapolis, MN, USA.
20 Sato I, Uppsala, Sweden.
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supplements were given for at least 1 week prior to and during the 
2-week study period.
lameness Examination
Evaluation of lameness was performed on the basis of a modifica-
tion of the AAEP lameness scale (22) on enrollment and at days 0, 
7, and 14 by one investigator (Alicia L. Bertone) unaware of group 
assignments. In a 30-m-long lameness examination area with a 
smooth, flat paved surface, lameness was graded with the horse 
being walked in one trip (30 ft back and forth—60 ft total), trotted 
in two trips with walking on the turns (to the left on the first 
trip and to the right on the second trip) and trotted in one trip 
after joint flexion in OA horses [30 s (lower limb) or 60 s (upper 
limb)] or after tendon/ligament pressure in ST horses (30  s). 
Lameness grades were as follows: 0 = not lame at the walk and 
trot, 1 = not lame at the walk and intermittently lame at the trot, 
2 = not lame at the walk and consistently lame at the trot under 
special circumstances of lunging, 3 = not lame at the walk and 
consistently lame at the trot on straight line, 3.5 = obviously lame 
at the trot on a straight line and lame at the walk on the turns, 
4 = lame at the walk and trot on a straight line, and 5 = partially or 
fully non-weight bearing at the walk. Additionally, using a scale 
of 1–9, horses were evaluated for severity to be added to their 
lameness score as a decimal place (e.g., a horse consistently, but 
minimally lame at the trot would be graded a 3.1 and a horse 
markedly and obviously lame at the trot, but not the walk, would 
be graded a 3.9). Flexion tests (OA) or palpation pain pressure 
tests (ST) were performed and a lameness grade reflecting the 
response to the correlating stress test was recorded. A lameness 
index was calculated as the sum of scores for baseline lameness 
(0–5), the severity score (0.1–0.9), and the scores for lameness in 
response to flexion test or palpation/pressure test [i.e., a lameness 
grade 3 with a severity grade 3 was recorded as a 3.3 and added to 
the score after joint flexion (e.g., 4) therefore this lameness index 
would be 7.3 (3 + 0.3 + 4)]. These lameness indices were then 
evaluated similarly to previous lameness data and reflected pain. 
In addition, the frequency of change in lameness was calculated by 
comparing the initial lameness score to the final day 14 lameness 
score for each horse and recorded as improved (score decreased), 
no change (score the same), or worsened (score increased).
Kinetic gait analysis
An examination aisle (3 m × 20 m) with a non-slip mat covered 
force plate21 and computer analysis system (see text footnote 21) 
was used for kinetic gait analysis of each horse at baseline, days 7 
and 14 (22). Force plate data were obtained following the subjec-
tive lameness scoring. Data sampling rate was 500 Hz, and data 
were filtered by a stop-band frequency of 80 Hz. Data collection 
included five valid strikes (passes) of the lame and contralateral 
limb for each time point. A valid measurement was defined as a 
passage by the horse over the force plate during which the hoof of 
the limb of interest fully contacted the surface of the plate and the 
gait velocity was within the range of 2.5–3.5 m/s. Should horses 
become too lame to keep the 2.5–3.5 m/s pace, their velocity ranges 
21 Kistler Instrument Corp., Amherst, NY, USA.
were reduced, recorded, and maintained at the slower velocity for 
the entire study for that horse. Vertical force peak (VFP; n/kg), 
vertical force impulse (VFI), and velocity were recorded (22). To 
adequately compare data that included forelimbs and hindlimbs, 
each horse was used as its own control and values were expressed 
as a ratio to baseline and as an asymmetry index (AI). AI between 
lame and contralateral limbs were expressed as a percent (21–23) 
and calculated as follows: 
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           (22).
imaging Examinations
Radiology
Standing cranio-caudal and lateral radiographs of the affected 
joint were taken at screening, and day 14 to meet inclusion crite-
ria or document a bone or joint adverse reaction. All radiographic 
images were assessed semi-quantitatively by an American College 
of Veterinary Radiology diplomate (Lisa J. Zekas), unaware 
of group assignments, and scored (0 =  none, 1 =  minimum, 
2 = mild, 3 = moderate, or 4 = marked) for osteophyte formation, 
joint narrowing, and sclerosis and irregularity of subchondral 
bone as well as the presence of subchondral bone cysts.
Ultrasound
Ultrasound examination of the standing sedated horse in cross 
and longitudinal section were similarly taken at screening, and 
days 7 and 14 to confirm the diagnosis in tendonitis or desmitis 
horses as well as for identification of the amount and location of 
inflammation in all horses and identification of short-term local 
adverse reactions. For flexor tendonitis or suspensory desmitis, a 
complete standard tendon/ligament ultrasound was performed, 
including longitudinal and cross-sectional images. For assess-
ment of swelling, a central longitudinal ultrasound was selected 
for the joint, tendon or ligament affected and subsequently 
measured (centimeters) for total depth (bone to skin), synovial 
fluid depth in joints only (bone to joint capsule margin), tendon 
thickness, and subcutaneous tissue thickness (Figure  4). To 
obtain consistent depth measurements of the joint capsule, the 
measurements at all time points began at a constant depth below 
the bones and constant width between the bones. The site of the 
ultrasound on the limb on day 0 was marked with a stainless 
steel staple and images were recorded for later analysis. The 
measurements were carried out through eFilm Workstation22 by 
two investigators blinded to treatment (Lisa J. Zekas and Logan 
Scheuermann).
Statistical analyses
All statistical analyses were performed by use of commercially 
available statistical software programs.23,24 The effects of injections 
22 eFilm Workstation® 4.0.3, Merge Healthcare, http://estore.merge.com, Academic 
License, 2016.
23 SAS, version 9.2, SAS Institute Inc., Cary, NC, USA.
24 STATA, version 11, Stata Corp LP, College Station, TX, USA.
FigUrE 4 | longitudinal ultrasonographic image of a radiocarpal joint 
detailing the measurements performed in the study for joints. (A) Joint 
fluid, (B) joint capsule, and (C) tendon and total depth were measured at the 
same site from skin to bone.
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on lameness scores, kinetic gait measurements, signs of inflamma-
tion (edema, limb circumference), goniometric range of motion, 
and pain on manipulation (flexion or pressure), and ultrasound 
measurements were analyzed by use of 2-factor repeated-meas-
ures ANOVA (factor 1 = treatment, factor 2 = time). Explanatory 
variables included horse, gender, limb (forelimb or hind limb; 
right or left), time points, and treatment (carrier vehicle or 
dental pulp tissue particles). Each horse was treated as a random 
variable, and repeated measures (time points) were considered 
to be nested within horse. For kinetic analyses, coefficients of 
variation (CV) were calculated for VFP, AI-VFP by dividing SD 
by the mean VFP. To test whether VFP was significantly altered 
by the classification of disease, the original data set was analyzed 
in total and divided into three disease groups (OA, desmitis, or 
tendonitis). Since there was no statistical difference between the 
ST injuries for desmitis and tendonitis, these were also combined 
for additional analyses. For each disease subset, repeated measure 
analysis was repeated as above.
Lameness parameters were also evaluated by analysis of the 
frequency of horses responding or not responding to treatment. 
Horses were categorized as responders if the changes in subjective 
lameness grades were decreased from day 0. Horses were catego-
rized as non-responders if the lameness grade increased from day 
0. The categories of responder or non-responder for lameness 
grade (days 7 and 14) were compared between the explanatory 
variables for frequencies by χ2 test. Lameness scores were also 
correlated to CV-VFP and AI-VFP using Pearson’s correlation 
coefficient.
Values of P ≤ 0.05 were considered significant for all analyses. 
In prior published work, lameness score, AI-VFP, and client 
scores had significant differences (P < 0.05) between treated and 
control groups in OA horses that indicated statistically significant 
improvement is lameness (22). Based on the means and SDs from 
that study, accepting a power of 0.8 and alpha error of 0.05, to 
detect, a priori, a difference in lameness score of 1, a difference 
in AI-VFP of 30%, and a difference in client score of 1, a sample 
size of three per group is sufficient25. Our study should be well 
powered with an n =  10 horses per category for our primary 
outcome variables.
rESUlTS
Horses
Forty client-owned horses (age range 2–17 years; mean 12.6 years; 
mean body weight 537 kg; 25 geldings, 1 stallion and 14 mares), 
meeting inclusion and exclusion criteria, and diagnosed with pain-
ful OA (n = 20), suspensory desmitis (n = 14), or tendonitis (n = 6) 
of the distal limb were enrolled in the study between December 
2013 and June 2014. Breeds represented were Warmblood Sport 
Horses (15), Quarter Horses (13), Thoroughbreds (6), Arabians 
(2), Standardbred, Morgan, Missouri Fox Trotter, and American 
Paint Horse at (1) each. Front limb lameness and hind limb 
lameness were not different between the treated (n = 13, n = 7, 
respectively) and control horses (n = 10, n = 10, respectively). 
There were no significant differences in right or left lame limb, 
breed distribution, age, gender, or body weight, between the 
treatment and control groups. All horses completed the study. No 
complications occurred in the preparation or injections of dental 
pulp tissue particles or control solution.
Physical Examination
The parameters of rectal temperature, pulse rate, and respiratory 
rate were out of reference ranges26 24 of 363 times and were 
deemed acceptable (Alicia L. Bertone). CBC parameters were 
within references ranges (see text footnote 17) and deemed 
acceptable in all horses. There were no significant differences in 
the physical examination parameters or CBC parameters between 
groups or across time.
Synovial Fluid Parameters
Synovial fluid was of sufficient volume for analysis at days 0 (10 of 
20 samples) and 14 (9 of 20 samples) in horses with OA. Synovial 
fluid WBC counts at day 0 and day 14 were within normal reference 
ranges (see text footnote 17) (<1,000 total cells/μL) with counts 
>1,000 cells/μL rare (two samples) and only seen with blood 
contamination. No significant difference in synovial fluid analysis 
was noted between treated- and control-OA horses. Synovial fluid 
from dental pulp tissue particle-treated joints had significantly 
lower concentrations of IL-6 (P < 0.03) and IL-10 (P < 0.03) on 
day 14 compared to day 0 while control joints had a significantly 
greater concentration of IL-6 and IL-10 on day 14 (P <  0.03) 
(Figure 5). There was no significant difference in IL-1ra or IL-1β, 
or their ratio in control or treated groups at any time point.
Edema/Swelling
Edema scores had a significant time effect (P <  3.3E−30) and 
were greater than baseline in injected horses in both groups up 
to and including day 10. Treated horses had greater edema score 
than control horses at days 2, 4, and 7 (P < 0.001) but both groups 
25 http://Statisticalsolutions.net.
26 Merck Manual Veterinary, Merck & Co., www.merckvetmanual.com, 2015.
TablE 3 | Parameters measured (mean ± SD) to assess inflammation and pain after injection of dental pulp tissue particles or carrier vehicle in horses 
with distal limb lameness due to osteoarthritis (Oa) or soft tissue (ST) injury of tendonitis or suspensory desmitis.
Parameter Disease group Day 0 Day 2 Day 4 Day 7 Day 10 Day 14
Edema 0–4 All C 0.09 ± 0.29 1.05 ± 0.7+,* 1.05 ± 0.8* 0.86 ± 0.8* 0.45 ± 0.67 0.23 ± 0.4
Tx 0 ± 0 1.55 ± 0.9+,* 1.6 ± 0.88+,* 1.5 ± 0.83* 0.65 ± 0.8 0.3 ± 0.66
Circumference (Δ mm 
from day 0)
All C+ (P<0.002) 0.54 ± 0.5 0.62 ± 0.6 0.19 ± 0.5 −0.09 ± 1.3 0.63 ± 2.1
Tx+ (P<0.002) 0.87 ± 0.8 0.64 ± 0.69 0.37 ± 0.65 0.24 ± 0.54 0.12 ± 0.45
ST# (P<0.004) C+ (P<0.004) 0.71 ± 0.6 0.6 ± 0.5 0.35 ± 0.36 −0.11 ± 1.6 0.26 ± 0.24
Tx+ (P<0.004) 0.73 ± 0.9 0.73 ± 0.9 0.58 ± 0.66 0.23 ± 0.56 0.12 ± 0.38
Pain score (0–4) All C 0.8 ± 0.9 0.4 ± 1.0 0.4 ± 1.0 0.9 ± 0.9 0.3 ± 0.9 0.6 ± 0.9
Tx 1.4 ± 1.7 0.6 ± 1.1 0.5 ± 1.1 1.1 ± 1.5 0.4 ± 0.8 1.1 ± 1.6
OA (to flexion) C 1.4 ± 1.7 1.6 ± 1.7 1.0 ± 1.1
Tx 2.3 ± 1.9 2.0 ± 1.8 1.9 ± 1.9
ST (to pressure) C 0.3 ± 0.9 0.4 ± 1.0 0.4 ± 1.0 0.3 ± 0.9 0.3 ± 0.9 0.3 ± 0.9
Tx 0.5 ± 1.1 0.6 ± 1.1 0.5 ± 1.1 0.4 ± 0.8 0.4 ± 0.8 0.4 ± 0.8
Joint range of motion 
(degrees)
OA C 118.6 ± 54.1 118 ± 61.2 122.7 ± 55.3 118.6 ± 60.4 118.5 ± 59.5 116.4 ± 60.2
Tx 119.6 ± 57.7 112.2 ± 58.3 118.4 ± 59.2 115.6 ± 56.5 117 ± 58.4 117.4 ± 58.1
*Differs between control and treated group (P ≤ 0.05).
+Differs from baseline within group (P ≤ 0.05).
#Differs across time within ST group (P ≤ 0.05).
FigUrE 5 | Mean ± SEM of the change in interleukin 10 (il-10) and 
interleukin 6 (il-6) concentration in synovial fluid of horses with 
osteoarthritis from before administration of dental pulp tissue 
particles (treated) or transport solution (control) on day 0, prior to 
injection (left bar) to day 14 after administration (right bar). Treated 
horses had a significant decrease and control horses a significant increase in 
IL-10 and IL-6 concentrations compared to baseline (P < 0.03).
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ranged from 0 to 3. Limb circumference data were expressed as 
a change from baseline (day 0) and showed no significant differ-
ence between groups but a significant effect of time (P < 0.04). 
The greatest increase in circumference was at day 2, then showed 
a decrease in limb circumference over time (Table 3).
Pain Scores and Pain-Free range  
of Motion in Oa Horses
Scores for pain on flexion of OA horses and pain on pressure for 
all ST horses showed no significant difference between groups or 
across time. A significant increase in pain induced lameness scores 
(on pressure test) specifically for tendonitis was noted (P < 0.04) 
with treated horses being more lame on pressure induced lame-
ness at days 7 and 14. Average goniometeric measurement for 
pain-free range of motion in OA horses showed no significant 
difference between treatment groups or time (Table 3).
lameness Scores
Lameness scores and lameness index (Table  4) showed that 
clinical trial horses were significantly improved with dental pulp 
tissue particle treatment compared to control horses (P < 0.013). 
Post-test analysis showed no significance difference between 
groups before injection at day 0, but a lower lameness score after 
injection in the treated group for day 7 and day 14 that was not 
seen in the control group (P <  0.007, P <  0.009 respectively). 
The treated group had a significantly greater number of horses 
that improved and with a sound gait at days 7 (P < 0.014) and 
14 (P < 0.02) compared to control horses. The odds that treated 
horses would respond were 9-fold (day 7) and 12.7-fold (day 14) 
more likely than control horses. Lameness grades in the ST horses 
were significantly lower in the treated compared to control horses 
(P < 0.0005) with the tendonitis horses showing a stronger sig-
nificant difference (P < 0.001) than the desmitis (P < 0.01) horses. 
Lameness scores within the OA horses improved, although not 
statistically significant, with treatment (P < 0.07) and ST horses 
showed greater improvement than OA horses (P < 0.001).
Kinetic gait analysis
Kinetic gait analysis was complicated by horses with moderate 
to marked lameness (grades 4 and 5) that did not permit col-
lection of all data at the predetermined velocities with four 
horses recorded at lower velocity (two control horses recorded 
at 2.0–3.0  m/s and two treated horses recorded at 0.5–1.5 or 
1.5–2.5  m/s, respectively). A slower velocity would appear as 
more lame (lower VFP) and would incorrectly appear as a lack 
of response to treatment or an underestimation of improvement. 
TablE 4 | lameness scores and indices (mean ± SD) to assess pain after injection of dental pulp tissue particles or carrier vehicle in horses with distal 
limb lameness due to osteoarthritis (Oa) or soft tissue (ST) injury of tendonitis or suspensory desmitis.
Parameter Disease group Day 0 Day 2 Day 4 Day 7 Day 10 Day 14
Lameness 0–5 All C 3.3 ± 0.7 3.3 ± 0.7 3.4 ± 0.5
Tx+ 3.4 ± 0.8a 2.7 ± 0.7b,^ 2.9 ± 0.6b,*
OA C 3.6 ± 0.6 3.7 ± 0.6 3.5 ± 0.6
Tx 3.9 ± 0.5 3.5 ± 0.4 3.7 ± 0.4
ST C 3.0 ± 0.4 2.9 ± 0.6 3.1 ± 0.1
Tx+ 2.9 ± 0.6a 1.9 ± 0.1b 2.1 ± 0.1b,*
Suspensory C 3.0 ± 0.5 2.8 ± 0.8 3.0 ± 0.1
Tx+ 3.0 ± 0.5a 2.2 ± 0.6b 2.5 ± 0.9a,b
Tendon C 3.0 ± 0 3.0 ± 0 3.0 ± 0
Tx+ 2.3 ± 0.5a 1.3 ± 1.0b 1.0 ± 1.1b
Lameness severity score (0.1–0.9) All C 0.4 ± 0.2 0.18 ± 0.3 0.2 ± 0.3
Tx 0.5 ± 0.3 0.4 ± 0.3 0.4 ± 0.3
OA C 0.4 ± 0.3 0.4 ± 0.3 0.3 ± 0.2
Tx 0.5 ± 0.3 0.6 ± 0.3 0.6 ± 0.3
ST C 0.5 ± 0.2 0.4 ± 0.2 0.5 ± 0.1
Tx 0.4 ± 0.2 0.2 ± 0.3 0.2 ± 0.3
Lameness response to flexion/pressure (0–5) All C 3.8 ± 1.0 3.7 ± 1.5 3.5 ± 1.5
Tx 3.8 ± 1.0 3.0 ± 1.7 3.0 ± 1.6
OA (to flexion) C 3.9 ± 0.9 4.2 ± 2.0 3.5 ± 1.8
Tx 4.4 ± 0.7 4.0 ± 1.5 4.0 ± 1.5
ST (to pressure) C 3.5 ± 0.8 3.4 ± 0.9 3.5 ± 0.8
Tx 3.2 ± 0.9 2.2 ± 1.7 2.2 ± 1.5
Lameness index All C 7.3 ± 1.4 7.3 ± 1.9 7.0 ± 1.3
Tx 7.6 ± 2.8 6.1 ± 3.18 6.3 ± 2.9
OA C 7.5 ± 1.7 8.0 ± 2.0 6.8 ± 1.8
Tx 8.8 ± 1.2 8.1 ± 1.3 8.2 ± 1.2
ST C 6.98 ± 1.0 6.6 ± 1.6 7.0 ± 1.0
Tx 6.4 ± 1.5 4.3 ± 3.4 4.5 ± 1.98
Lameness index is the sum of the lameness score, the lameness severity score, and the lameness score after joint flexion (OA) or pressure (ST). Total possible score 10.9. 
Significance only denoted for lameness parameter.
*P < 0.05 between control and treated group.
+P < 0.04 differs from baseline within group.
^P < 0.07 between control and treated group.
P < 0.01 different letter superscripts differ from baseline within group.
11
Bertone et al. Dental Pulp Clinical Trial
Frontiers in Veterinary Science | www.frontiersin.org March 2017 | Volume 4 | Article 31
Regardless, velocity did not significantly differ between groups or 
across trials. AI-VFP and CV-VFP decreased with time and had 
interactions with treatment and disease. AI-VFP and CV-VFP 
decreased compared to baseline in pulp-treated horses (P ≤ 0.05), 
particularly within treated OA horses, both corresponding to 
less lameness. Pulp-treated horses started with a mean of 11% 
AI-VPF and at day 14 and ended with a mean of 6% AI-VPF, 
an almost 2-fold improvement toward soundness. AI-VFI in 
OA (P < 0.04) horses and CV-VPI (P < 0.03) was lower in the 
pulp-treated horses compared to baseline that was not seen in 
the control horses, both corresponding to less lameness. When 
ST horses (n = 10 treated and n = 10 control) were evaluated as 
a subset of all horses, the CV-VFP was significantly decreased 
in treated horses at day 14 compared to control horses at day 
14 and tended to be lower than baseline, indicating less lame-
ness. Pulp-treated horses had CV-VPF transition from a mean 
of 6% CV at baseline to a mean of 3.5% CV at 14  days, again 
a similar ~2-fold improvement corresponding to improvements 
in lameness. For the sound contralateral limbs in these horses, 
CV-VFP was a mean of 6.4 at baseline and remained at 6.8% CV 
at day 14 showing no change. These parameters correlated with 
the significant improvement of lameness scores for this subset of 
treated horses (P < 0.007).
Client Questionnaires
Client scores decreased (corresponding to improvement) across 
time (P  <  0.001), significantly in four categories (lameness, 
comfort in stall, comfort in turnout, and general attitude) by day 
45 (Figure 6). At long-term follow-up, >2.5 years after injection, 
20 clients responded to the questionnaire which corresponded to 
a 50% response rate. Of the 20 responses, four horses had died 
or were euthanized for reasons unrelated to the injection or OA/
ST injury. Of the 16 responding clients with live horses, 12 com-
mented on the use of the horse and of the 12, 10 horses (83%) 
were being ridden (two at national competition level). The two 
horses not being ridden were at pasture, one as a brood mare and 
one retired. Seven of the 10 horses in work were sound (score 0).
Owner Selection for additional Treatment
All horse owners in the control group opted to receive the dental 
pulp tissue particle injection after the termination of the study. 
FigUrE 6 | graph of mean ± SEM client survey scores for 
assessment of lameness and discomfort before (baseline), 21 days 
post-injection, and 45 days post-injection of dental pulp tissue 
particles. Client scores decreased across time (P < 0.001), significantly in 
four categories (lameness, comfort in stall, comfort in turnout, and general 
attitude) by day 45.
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Twelve of the 20 horse owners in the treated group opted for at 
least one more injection after the end of the data collection phase 
at 45 days and two horses received three injections. No adverse 
events were noted in these horses and no horses worsened in 
lameness.
DiSCUSSiOn
This prospective, randomized, blinded, and controlled clinical 
trial is the first to show that viable dental pulp tissue particles were 
effective to improve lameness when injected into an OA joint or 
injured tendon or ligament compared to a placebo-control solu-
tion within 1 week that sustained for at least 2 weeks. The client 
assessment survey for lameness and other parameters of comfort 
showed significant improvement from baseline that was sustained 
for at least 45 days supporting the findings from the controlled 
clinical trial. Clients were satisfied with the level of comfort of 
their horse and the injection. Clients reported that no horses 
during these 45 days had a life-threatening event or worsening of 
the lameness. Long-term follow-up (range 2.5–3 years) had many 
horses sound and in use without adverse events or worsening of 
the condition or lameness. Interestingly, horses with ST injury 
improved in lameness to a greater degree than OA horses. It is 
reasonable that the dental pulp tissue particles were more effec-
tive in ST injury possibly due to similarity of connective tissue 
phenotype or possibly ST injuries heal better than degenerative 
cartilage in OA. ST injury horses may also have had less chronic 
and less permanent injury than OA horses. All horses had to be 
lame for >1 month to meet inclusion criteria, but OA horses had 
to have visible changes on a radiograph that likely required the 
disease to be ongoing for longer than 1 month. In the case of ST 
injury, it would have been possible for the injury to be just over 
the 30-day criteria and still meet the lameness and ultrasound 
criteria. Further study correlating duration of ST injury, presence 
of fibrosis, and size of lesion with outcome is warranted to further 
define the treatment recommendations. Another explanation for 
less response by OA horses is that a hallmark of OA is cartilage 
damage and many of these horses may have had permanent 
injury that is beyond pain relief or restoration at least within the 
time frame of this study.
Our synovial fluid data demonstrated lack of persistent inflam-
mation in the joint fluid by 2 weeks after injection. This was antici-
pated based on our preliminary data in which the inflammatory 
response of the joint was transient and returned to normal even 
in OA joints by day 7 (Figure 2). Importantly, however, there was 
a persistent (at least to 2 weeks) significant decrease in two key 
inflammatory cytokine interleukins in the treated group that was 
actually increased in the control group. This anti-inflammatory 
effect of dental pulp tissue particles in OA joints may provide a 
longer term influence that could benefit cartilage at a later time 
point than was studied here. To have been able to evaluate the 
healing or regeneration of cartilage in OA, or ST, horses, would 
have required an 8–12  months controlled experimental model 
study or clinical trial that is not only costly but often requires 
invasive surgery, costly MRI, or euthanasia to obtain tissue sam-
ples for quantification of results. Well controlled clinical trials, 
as performed here, offer the advantage of not only determining 
efficacy of a treatment but also effectiveness in natural occurring 
disease states that have comorbidities and expectations of return 
to work for this cohort. Importantly, our study focused on prov-
ing effectiveness of dental pulp tissue particles as a treatment to 
improve lameness using these three target diseases that have been 
shown to respond to MSC in many other studies as summarized 
in Section “Introduction.” To accomplish this goal, only 2 weeks 
of the prospective, blinded, randomized, and placebo-controlled 
clinical trial with quantitative metrics was needed. Client assess-
ments of lameness and comfort in a prospective study using a 
validated survey also supported improvement in discomfort and 
lameness from baseline out to 45 days. No horses were able to 
work prior to enrollment, no horses worsened in ST injury or 
progressed in OA as measured in the short term by ultrasound 
or radiograph, respectively. Of the clients that commented on 
current use of the horse in the final questionnaire at >2.5 years, 
83% commented their horses were in work and being ridden. In 
concert, these data support a pain-relieving effect lasting longer 
than most conventional pain medications without repeated dos-
ing and an anti-inflammatory biomarker change in the joint fluid 
of OA horses at 2 weeks supporting a biologic improvement in 
joint environment.
The design of this study represented a hybrid clinical trial with 
a primary outcome of pain relief. Client-owned animals with 
natural occurring clinical disease were kept in the hospital for 
quantitative assessments to control for many factors known to 
affect lameness, such as exercise, stall size, and evaluators. A team 
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of qualified and trained handlers and evaluators, blinded to treat-
ment, were used for the lameness examinations, physical exami-
nations, and subjective semi-quantitative scoring of edema, pain 
on pressure, pain on flexion, or pain-free range of joint motion. 
Our study design permitted the use of fewer animals than a typi-
cal field trial (51) in which hundreds of horses often participate. 
In our study, clients evaluated relevant parameters that did not 
duplicate our assessments of lameness, but were additive. Horses 
were evaluated in the home environment and owners co-signed 
that their horses were maintained in the same environment situ-
ations as the baseline assessments providing other controls that 
strengthen these client assessments over typical field trials. Our 
reports using similar hybrid models of OA in horses (22) have 
confirmed that the use of these hybrid clinical trials has reduced 
the coefficient of variance for the force plate, for example to 
between 6 and 8% (52, 53), an acknowledged low animal vari-
ability, even for experimental animal models of lameness. These 
studies also offer the option for a client assessment study with 
the collection of data on client opinion and perception of their 
animal improvement which can give an estimate of the public 
reception to the treatment. In dogs with OA, similar standard-
ized client questionnaires (21, 23) have been used to observe the 
well accepted measures of pain at home, such as climbing stairs, 
jumping into the car or on the couch, getting up for treats, or 
circling before bedding. These instrument surveys capture these 
subjective but valid assessments at home. The first four categories 
in our survey have been validated to correlate to lameness scores 
on the same animal and lameness on the force plate (22) (see 
text footnote 16). Our goal with the client assessment was to 
capture other more subjective assessments that could represent 
discomfort. Indeed, these first four categories were statistically 
significantly improved in the 21- and 45-day assessment. Post-
analysis of data showed that random case assignment did not 
inadvertently bias this study for front versus hind lameness, right 
versus left limb affected, cause of disease, severity of baseline 
lameness, gender, age, or breed.
Use of allogeneic intra-articular cells in horses has met with 
mixed recommendations. An earlier paper published a statisti-
cally insignificant, but increased inflammatory response to 
allogeneic compared to autologous placenta-derived MSC that 
was less with half-siblings (11). Recent papers reported lack of 
induced lameness or adverse reactions following injection of 
MSC into cartilage defects or OA in stifle joints of horses (27, 
28, 30). Allogeneic bone marrow-derived cultured MSC injected 
as 5 × 107/mL into fetlock joints caused a greater peak transient 
inflammatory response than autologous cells, but less than 
xenogeneic cells (4). Only xenogeneic cells invoked immune 
activation as measured by number of CD8+ T cells or inflam-
matory cytokine production when injected MSC were cultured 
back with the horse’s peripheral blood monocytes taken 120 days 
after original MSC intra-articular injection (19). In concert, 
these data suggested that an immune or inflammatory reaction 
to allogeneic cells is either lowly detectable or undetectable, 
without recognizable clinical effects, and for at least 120  days. 
Our data from this study would corroborate these findings as a 
mild and transient inflammation. Further safety studies looking 
at the immune-tolerance of the allogeneic pulp are warranted. 
The advantages of the use of allogeneic cells are many, most 
importantly an “off the shelf ” access and full characterization of 
the product. In the case of this dental pulp tissue particle product, 
characterized as containing CD44, CD90, and CD105 positive 
cells reflecting a mesenchymal progenitor as well as CD34 and 
CD45 hematopoetic progenitor profile, can be available within 
24 h of order for injection in practice.
The current study had minimal inflammation in the acute 
phase after injection that was transient in both groups and 
resolved rapidly. We reported similar findings for autologous pro-
tein solution (22). The inflammation was mild and focal around 
the injection site and, as expected, was greater in the pulp-treated 
group. We elected to not treat these horses with anti-inflammatory 
medications or a pressure bandage so as not to interfere with our 
outcome assessments. These recommendations, that are standard 
in practice, would be expected to completely eliminate these 
signs. Although non-steroidal anti-inflammatory drugs are often 
withheld after platelet concentrate injections so as to not suppress 
platelet activation and release of growth factors, to the authors’ 
knowledge, there is no known interaction of non-steroidal anti-
inflammatory drugs and dental pulp tissue particles. Importantly, 
there were no adverse events or worsening of lameness at any time 
point in the study.
This study did have some limitations. Our study was designed 
to prove that dental pulp tissue particles could reduce lameness 
and pain in natural occurring disease conditions in horses. Our 
study was not designed to prove the duration of the effective-
ness nor the regenerative or healing potential of these particles. 
A different design and longer term controls would have been 
necessary to prove the duration. Although our study did supply 
client assessment studies that support an effect to at least 45 days 
compared to the baseline this is a lower level of evidence due to 
lack of matched untreated controls or vehicle controls for the same 
time period. These follow-up assessments also provide evidence 
that the product, administered at this clinical dose, was not visibly 
harmful to the horse or the condition out to 45 days (>6 weeks) 
based on the client assessment. Our study does not determine 
if other longer term changes in the disease or tissues could be 
associated with injection. A full safety study of the product would 
likely include study at doses higher than recommended clinically. 
Another limitation of any biologic study is the unknown metric 
to guide dosing. Biologic products in horses are not currently 
dosed on body weight or any recommendations based on lesion 
size or severity. Our selection of a single dose for all horses may 
have contributed to variability in our findings, but this guiding 
information is not currently available.
In our study, the force plate data corroborated our lame-
ness scores with statistically significant correlations and shift 
in AI-VFP and CV-VFP in the direction that corresponded 
to greater loading of the limb and less variability step-to-step 
(22, 52, 53). The AI-VFP parameter is used preferentially in studies 
in which both forelimb and hindlimb lameness are included since 
AI-VFP measures the normalized difference in the VFP between 
the lame limb and the contralateral limb (22). If a horse is chang-
ing from lameness toward soundness, the difference between 
14
Bertone et al. Dental Pulp Clinical Trial
Frontiers in Veterinary Science | www.frontiersin.org March 2017 | Volume 4 | Article 31
the lame and contralateral limb will approach 0. Variability in 
limb loading step-to-step (CV-VPF) has been another param-
eter that has directly correlated to degree of lameness in other 
studies (52, 53). Horses with lameness place load on the lame 
limbs inconsistently, producing greater variability (CV) within 
the five valid trials recorded in these studies. Pulp-treated horses 
significantly reduced CV-VFP from a mean of 6–3.5%, not seen 
in the controls. Overall, despite some limitations in the force plate 
data collection, the findings correlated highly with our lameness 
scores and supported our findings of a reduction in lameness in 
horses with OA, tendonitis, or desmitis that were treated with 
dental pulp tissue particles.
In summary, a single intra-articular dose of 10 × 106 dental 
pulp tissue particles in 2  mL of sterile isotonic buffered saline 
solution significantly improved lameness in horses with OA or 
ST equine injuries compared to the same solution without dental 
pulp tissue particles. Minimal transient edema, greater than con-
trol, was localized to the injection site out to day 7. Dental pulp 
tissue particles had significantly lower inflammatory mediators 
in the OA synovial fluid after treatment that actually increased 
in the controls, and significantly improved client scores for 
lameness and comfort at 21 and 45 days. Of the 12 clients that 
commented on current use of the horse in the final questionnaire 
at >2.5 years, 10 commented their horses were in work and being 
ridden. In conclusion, use of dental pulp tissue particles was effec-
tive in the treatment of pain and lameness due to OA, tendonitis, 
or desmitis, and represents an injectable therapeutic choice that 
has regenerative potential.
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